Nodal Marginal Zone Lymphoma: Impersonalized Medicine Cancer Network [12] More recently, impressive response rates coupled with manageable toxicity have created significant interest in the use of bendamustine with rituximab for indolent NHLs; however, the results of the study from which these data derive have not yet ... |
